April 14th, 2025 “EURETINA-Brief”© Issue No. 314
Dear EURETINA Members, A very warm welcome to the April 14th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
April 14th, 2025
Latest News
April 14th, 2025 “EURETINA-Brief”© Issue No. 314
Dear EURETINA Members, A very warm welcome to the April 14th, 2025 edition of EURETINA’s…
Novel research on a gene-agnostic strategy to treat RP aims to improve cone cell survival and extend vision.
Researchers at the Department of Genetics, and the Department of Ophthalmology, Harvard Medical School, Boston,…
Clinical analysis of phenotypic and genotypic characteristics on retinitis pigmentosa-1-like-1 (RP1L1) show associated retinopathy.
Clinical researchers at the Sorbonne Université, INSERM, Institut de la Vision, Paris, have reported multiple…
Atsena Therapeutics has announced the grant of U.S. FDA Fast Track Designation for ATSN-201 gene therapy for the treatment of X-linked retinoschisis.
Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug…